Multiple Sclerosis: Treatment delays the need for a wheelchair

An important benefit for patients with primary progressive multiple sclerosis in delaying disability consolidation and the need to use a wheelchair is treatment with the monoclonal antibody octrelizumab.

The treatment is given every six months without the need for special dosing examinations and is approved in over 60 countries in North America, South America, the Middle East, Eastern Europe, and Australia, Switzerland and the European Union .

These are data from the phase III study ORATORIO presented at the 4th International Congress of the European Neurology Academy in Lisbon.

In particular, subjects treated with ocrelizumab had a 46% reduction in the risk of wheelchair aggression compared to the placebo group (6.2% vs 9.8% of the risk, respectively, p = 0.022 ). When these results were broadened to calculate average wheelchair use time, the data showed that the monoclonal antibody may delay the need for a wheelchair for seven years.

The study also showed that patients in the control group had similar rates of disability progression with a population of patients not treated for the same form of MS.

“For a person living with primary multiple sclerosis who have twice the risk of disability from the Intermittent CP, seven additional years without the need for a wheelchair means that he can live with more independence, continue working or taking care of the family of. The data presented in the EAN show the significant incidence of ocrelizumab as the first modifying treatment of the primary multiple sclerosis already approved in more than 60 countries and may cover up to now unmet needs of multiple sclerosis patients ” Professor and chair of the Research for Multiple Sclerosis and Neuroanalysis at Monash University, Helmut Bouzkeveen.

The estimated wheelchair need time (EDSSā‰„7) for placebo-treated patients in the ORATORIO study was 12.1 years compared to 12.4 years for those with primary MSBase enrolled in the MSBase registry.

The treatment safety data presented in EAN 2018 is consistent with the desired benefit-risk profile. The most common adverse reactions associated with ocrelizumab were infusion-related reactions and infections of the upper respiratory tract, which were predominantly mild to moderate in severity.

It is recalled that multiple sclerosis is estimated to affect about 700,000 people in Europe, of whom approximately 96,000 are primarily developing in a form with a high level of disability. Most people with multiple sclerosis exhibit recurrent or primary progressive diagnosis.